Natural adaptive immunity co-evolved with pathogens over millions of years, and adoptive
transfer of non-engineered T cells to fight infections or cancer so far exhibits an …

Therapeutic T cells with desired specificity can be engineered by introducing T-cell
receptors (TCRs) specific for antigens of interest, such as those from pathogens or tumour …

Adoptive T cell therapy using T-cell receptor (TCR)-engineered T cells allows to redirect T
cell specificity and to target any antigen of interest. Here, we apply advanced genetic …

Adoptive-cell therapy, including the transfer of tumor-infiltrating T lymphocytes after in vitro
expansion or T cells redirected to tumor antigens using antigen-specific transgenic T-cell …

Adoptive transfer of T cells expressing a transgenic T cell receptor (TCR) has the potential to
revolutionize immunotherapy of infectious diseases and cancer. However, the generation of …

Objectives Exploiting the forces of human T cells for treatment has led to the current
paradigm of emerging immunotherapy strategies. Genetic engineering of the T‐cell receptor …

Viral infections cause life-threatening disease in immunocompromised patients and
especially following transplantation. T cell receptor (TCR) engineering redirects specificity …

Adoptive transfer of T-cell receptor (TCR)-engineered T cells has been successful in
mediating favorable clinical outcomes. TCR-engineered T cells can be applied for targeting …

Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Adoptive transfer of T cells genetically modified to express a cancer-specific T-cell receptor
(TCR) has shown significant therapeutic potential for both hematological and solid tumors …